רוקחות-פרמקולוגיה

AACE: Long-term Lipid Benefits of Pioglitazone Appear For Type 2 Diabetics

By Bruce Sylvester
Special to DG News

CHICAGO, IL — May 3, 2002 — Type 2 diabetics receiving one year of pioglitazone therapy at 45 mg/day showed improved high-density lipoprotein (HDL) cholesterol levels as well as lowered glycemic and triglyceride levels, researchers reported here yesterday at the annual meeting of the American Association of Clinical Endocrinologists.

"These changes should have a positive benefit on coronary heart disease associated with diabetes," the researchers concluded.

The investigative team, led by Allen King, MD, Medical Director of the Diabetes Care Center in Salinas, California, United States, did a retrospective analysis of the charts of patients with type 2 diabetes who had received pioglitazone at 45 mg/day and whose hemoglobin A1c (HbA1c) and lipid panel values had been recorded at intervals appropriate for this retrospective analysis.

Excluded from the study were patients whose pioglitazone treatment had been interrupted and patients whose dosage of lipid lowering drug had been altered during the course of a 12-month treatment or within six weeks of the initiation of pioglitazone therapy.

לכתבה המלאה

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ e-Med
 כל הזכויות שמורות

 

התכנים המוצגים באתר זה מיועדים לאנשי צוות רפואי בלבד

אם כבר נרשמת, יש להקליד את פרטי הזיהוי שלך
עדיין לא נרשמת? באפשרותך לבצע רישום כאן
להרשמה לאתר